Clinical experience of tolcapone in advanced Parkinson's disease

Margherita Canesi, Anna Lena Zecchinelli, Gianni Pezzoli, Angelo Antonini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We are reporting our clinical experience in 66 patients with advanced Parkinson's disease (PD) who were switched to tolcapone because of persisting off periods despite treatment with entacapone (according to the European Agency for the Evaluation of Medicinal products: EMEA). We used UPDRS II-III-IV in "on" state to monitor tolcapone effectiveness at 6 and 12 months. We found significant reductions in mean off-time duration (UPDRS item 39) and levodopa dose at follow up. Eleven patients dropped out (17%) during the first month of treatment, 2 (3%) because liver enzymes exceeded normal limit. Amongst patients who continued tolcapone, 30/55 (54%) reported "off-time" reduction ≥25% (UPDRS-39 decrement ≥1 point). Our findings indicate that tolcapone widens the levodopa therapeutic window, even in patients who have not benefited from entacapone. We suggest that tolcapone is indicated before patients are referred for more invasive procedures.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 5
DOIs
Publication statusPublished - 2008

Fingerprint

Parkinson Disease
Levodopa
Therapeutics
tolcapone
Liver
Enzymes
entacapone

Keywords

  • Advanced Parkinson's disease
  • Entacapone
  • Switch
  • Tolcapone
  • UPDRS

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Canesi, M., Zecchinelli, A. L., Pezzoli, G., & Antonini, A. (2008). Clinical experience of tolcapone in advanced Parkinson's disease. Neurological Sciences, 29(SUPPL. 5). https://doi.org/10.1007/s10072-008-1052-9

Clinical experience of tolcapone in advanced Parkinson's disease. / Canesi, Margherita; Zecchinelli, Anna Lena; Pezzoli, Gianni; Antonini, Angelo.

In: Neurological Sciences, Vol. 29, No. SUPPL. 5, 2008.

Research output: Contribution to journalArticle

Canesi, M, Zecchinelli, AL, Pezzoli, G & Antonini, A 2008, 'Clinical experience of tolcapone in advanced Parkinson's disease', Neurological Sciences, vol. 29, no. SUPPL. 5. https://doi.org/10.1007/s10072-008-1052-9
Canesi, Margherita ; Zecchinelli, Anna Lena ; Pezzoli, Gianni ; Antonini, Angelo. / Clinical experience of tolcapone in advanced Parkinson's disease. In: Neurological Sciences. 2008 ; Vol. 29, No. SUPPL. 5.
@article{b9de97429e4040c6898e9d8578a7bd4e,
title = "Clinical experience of tolcapone in advanced Parkinson's disease",
abstract = "We are reporting our clinical experience in 66 patients with advanced Parkinson's disease (PD) who were switched to tolcapone because of persisting off periods despite treatment with entacapone (according to the European Agency for the Evaluation of Medicinal products: EMEA). We used UPDRS II-III-IV in {"}on{"} state to monitor tolcapone effectiveness at 6 and 12 months. We found significant reductions in mean off-time duration (UPDRS item 39) and levodopa dose at follow up. Eleven patients dropped out (17{\%}) during the first month of treatment, 2 (3{\%}) because liver enzymes exceeded normal limit. Amongst patients who continued tolcapone, 30/55 (54{\%}) reported {"}off-time{"} reduction ≥25{\%} (UPDRS-39 decrement ≥1 point). Our findings indicate that tolcapone widens the levodopa therapeutic window, even in patients who have not benefited from entacapone. We suggest that tolcapone is indicated before patients are referred for more invasive procedures.",
keywords = "Advanced Parkinson's disease, Entacapone, Switch, Tolcapone, UPDRS",
author = "Margherita Canesi and Zecchinelli, {Anna Lena} and Gianni Pezzoli and Angelo Antonini",
year = "2008",
doi = "10.1007/s10072-008-1052-9",
language = "English",
volume = "29",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Clinical experience of tolcapone in advanced Parkinson's disease

AU - Canesi, Margherita

AU - Zecchinelli, Anna Lena

AU - Pezzoli, Gianni

AU - Antonini, Angelo

PY - 2008

Y1 - 2008

N2 - We are reporting our clinical experience in 66 patients with advanced Parkinson's disease (PD) who were switched to tolcapone because of persisting off periods despite treatment with entacapone (according to the European Agency for the Evaluation of Medicinal products: EMEA). We used UPDRS II-III-IV in "on" state to monitor tolcapone effectiveness at 6 and 12 months. We found significant reductions in mean off-time duration (UPDRS item 39) and levodopa dose at follow up. Eleven patients dropped out (17%) during the first month of treatment, 2 (3%) because liver enzymes exceeded normal limit. Amongst patients who continued tolcapone, 30/55 (54%) reported "off-time" reduction ≥25% (UPDRS-39 decrement ≥1 point). Our findings indicate that tolcapone widens the levodopa therapeutic window, even in patients who have not benefited from entacapone. We suggest that tolcapone is indicated before patients are referred for more invasive procedures.

AB - We are reporting our clinical experience in 66 patients with advanced Parkinson's disease (PD) who were switched to tolcapone because of persisting off periods despite treatment with entacapone (according to the European Agency for the Evaluation of Medicinal products: EMEA). We used UPDRS II-III-IV in "on" state to monitor tolcapone effectiveness at 6 and 12 months. We found significant reductions in mean off-time duration (UPDRS item 39) and levodopa dose at follow up. Eleven patients dropped out (17%) during the first month of treatment, 2 (3%) because liver enzymes exceeded normal limit. Amongst patients who continued tolcapone, 30/55 (54%) reported "off-time" reduction ≥25% (UPDRS-39 decrement ≥1 point). Our findings indicate that tolcapone widens the levodopa therapeutic window, even in patients who have not benefited from entacapone. We suggest that tolcapone is indicated before patients are referred for more invasive procedures.

KW - Advanced Parkinson's disease

KW - Entacapone

KW - Switch

KW - Tolcapone

KW - UPDRS

UR - http://www.scopus.com/inward/record.url?scp=65449151834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449151834&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-1052-9

DO - 10.1007/s10072-008-1052-9

M3 - Article

C2 - 19381768

AN - SCOPUS:65449151834

VL - 29

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 5

ER -